Posts Tagged: Paul Santerre
The University of Toronto and its partners are receiving $4.25 million over the next five years to establish a national hub aimed at accelerating the commercialization of life sciences discoveries.
The Discovery Grant program is dedicated to supporting researchers as they venture into new territories to find solutions to pressing issues such as environmental protection, food security, and sustainable construction in cold climates. It aims to promote and maintain a diverse and high-quality research capability in the natural sciences and engineering at Canadian universities, foster research excellence, and provide a stimulating environment for research training.
Completed her Ph.D. in Dr. Paul Santerre’s lab in 2019, Dr. Meghan Wright always had a passion for entrepreneurship, business, and science. After graduating, Meghan interned briefly with the life sciences investment firm Bloom Burton & Co. as a consultant before joining Shift Health, a life sciences and healthcare strategy consulting firm located in Toronto. Now Meghan is working on projects across a wide range of areas – from the private sector to academia, to help transform healthcare.
In the 4th volume of Nature’s Communications Biology, researchers at TBEP published an important study that can reshape the way we engineer new blood vessels for patients who need them.
An innovative biomaterial discovery by researchers at the University of Toronto in collaboration with Ripple Therapeutics Inc., has established a method that yields better control over drug release profiles in implants and has the potential to disrupt the classical drug delivery market.
Graduate students and post-doctoral researchers who want to translate regenerative medicine research or technology into a product or venture can now take their first steps toward becoming an entrepreneur through a new University of Toronto program.
Paul Santerre, a professor in the Faculty of Dentistry and the Institute of Biomedical Engineering, says the extent of progress on diabetes and insulin will partly depend on how well research breakthroughs from scholars like Brubaker can be married with efforts at commercialization and innovation.
Paul Santerre receives lifetime achievement award from Canadian Biomaterials Society
Interface Biologics's (IBI) antithrombogenic additive have been used in a new line of FDA-approved "breakthrough" dialysis products made by IBI's partner, Fresenius Medical Care.
Showing 1 - 10 of 32 results